<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02047877</url>
  </required_header>
  <id_info>
    <org_study_id>13-2784</org_study_id>
    <nct_id>NCT02047877</nct_id>
  </id_info>
  <brief_title>Airway Inflammatory Response During Illness in Children With Respiratory Failure</brief_title>
  <official_title>Investigation of Airway Inflammatory Response During an Acute Respiratory Illness in Pediatric Patients With Respiratory Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of North Carolina, Chapel Hill</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study has two major goals: 1) to measure the amount of two specific
      hormones interleukin (IL)-10 and interleukin (IL)-12p70 in mucous and blood; and 2) compare
      the hormone levels in two specific areas of the lung called the trachea (upper airway) and
      the bronchioles (lower airway). The hormones IL-10 and IL-12p70 are cytokines, special
      hormones cells use to communicate with each other during inflammation or infection. Cytokines
      can be measured in mucous and blood. The balance of one cytokine compared to another help
      doctors to understand how people respond differently to infection. Unfortunately, the amount
      of IL-10 and IL-12p70 is not known in children, especially children with a lung infection. In
      addition, we do not know if the balance of these cytokines differ in various regions of the
      lung. We believe the balance of IL-10 and IL-12p70 is similar whether measured in the upper
      or lower airways.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed to measure the concentration and describe the distribution of cytokine
      IL-10 and IL-12p70 in a previously healthy pediatric population suffering direct lung injury
      by an infectious etiology, not yet described in the literature.

      In addition, this study seeks to determine whether tracheal aspirates (TA) obtained in early
      acute respiratory failure can be substituted for distal airway aspirates, obtained by
      non-bronchoscopic broncho-alevolar lavage (nb-BAL), for the purposes of investigating markers
      of inflammation. We will compare the ratio of IL-10 to IL-12p70 at each time point measured
      in tracheal secretion, bronchial secretion, and blood to assess for sample equivalence.

      Finally, this study will affirm the safety profile for repeated nb-BAL, establish a protocol
      for respiratory sample collection and storage for future larger scale studies, and generate
      feasibility data regarding consent rate, estimates of data completion, and fraction of
      missing data for us to determine whether a future study involving the ratio of IL-10 to
      IL-12p70 can be used as a predictor of acute respiratory distress syndrome (ARDS) in this
      population.

      The data generated by this study regarding safety, comparison of nb-BAL and TA, and cytokine
      concentrations will be used as preliminary data informing the design of a larger multicenter
      study testing the hypothesis that IL-10 and IL-12p70 levels in airway secretions can predict
      risk for ARDS in this population. This may be approached via application to the Pediatric
      Acute Lung Injury and Sepsis (PALISI) clinical research network group.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Study concept vacated due to sample collection issues
  </why_stopped>
  <start_date type="Anticipated">July 2017</start_date>
  <completion_date type="Anticipated">August 2019</completion_date>
  <primary_completion_date type="Anticipated">August 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mean log transformed IL-10:IL-12p70 ratio in tracheal secretion, bronchial secretion, and serum within 48-hours of mechanical ventilation</measure>
    <time_frame>Within 48 hours of mechanical ventilation</time_frame>
    <description>Tracheal aspirates (TA), bronchial fluid (nb-BALF), and blood are collected within 48-hours following endotracheal intubation. All three samples are collected again at two additional time points following intubation: between days 3-4 and between days 5-7, so long as the patient remains endotracheally intubated. Three time points were chosen to show consistency in ratio of IL-10 to IL-12p70 between TA and nb-BALF throughout the first week of endotracheal intubation. If a patient is extubated before day 7 all sample collection will stop. No samples will be obtained after 7 days of intubation as we are focusing on the acute phase of lung injury only. An ELISA assay is performed to measure the concentration of IL-10 and IL-12p70 for ratio comparison.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood oxygenation saturation and hemodynamic changes following non-bronchoscopic BAL</measure>
    <time_frame>Baseline through 1-hour post procedure</time_frame>
    <description>Pulse Oxygen Saturation (SpO2), heart rate (HR), blood pressure (BP), and cardiac rhythm are continuously monitored per clinical routine in intubated patients. These parameters will be recorded pre-procedure then monitored over the 1 hour post-procedure. Transient and inconsequential changes in these parameters are expected. The following changes will be considered adverse events and reported to data safety monitor (DSM):
Persistent (&gt;10 minute) decrease in SpO2 of more than 10% below pre-procedure baseline during the 1-hour post-procedure.
Persistent (&gt;10 minute) increase in HR of more than 30 beats per minute above pre-procedure baseline during the 1-hour post-procedure.
Persistent (&gt;10 minute) decrease in MAP of more than 15 mm Hg below pre-procedure baseline during the 1-hour post-procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean log transformed IL-10:IL-12p70 ratio in tracheal secretion, bronchial secretion, and serum between days 3-4</measure>
    <time_frame>Days 3 to 4 of mechanical ventilation</time_frame>
    <description>Tracheal aspirates (TA), bronchial fluid (nb-BALF), and blood are collected within 48-hours following endotracheal intubation. All three samples are collected again at two additional time points following intubation: between days 3-4 and between days 5-7, so long as the patient remains endotracheally intubated. Three time points were chosen to show consistency in ratio of IL-10 to IL-12p70 between TA and nb-BALF throughout the first week of endotracheal intubation. If a patient is extubated before day 7 all sample collection will stop. No samples will be obtained after 7 days of intubation as we are focusing on the acute phase of lung injury only. An ELISA assay is performed to measure the concentration of IL-10 and IL-12p70 for ratio comparison.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean log transformed IL-10:IL-12p70 ratio in tracheal secretion, bronchial secretion, and serum between days 5-7</measure>
    <time_frame>Days 5 to 7 of mechanical ventilation</time_frame>
    <description>Tracheal aspirates (TA), bronchial fluid (nb-BALF), and blood are collected within 48-hours following endotracheal intubation. All three samples are collected again at two additional time points following intubation: between days 3-4 and between days 5-7, so long as the patient remains endotracheally intubated. Three time points were chosen to show consistency in ratio of IL-10 to IL-12p70 between TA and nb-BALF throughout the first week of endotracheal intubation. If a patient is extubated before day 7 all sample collection will stop. No samples will be obtained after 7 days of intubation as we are focusing on the acute phase of lung injury only. An ELISA assay is performed to measure the concentration of IL-10 and IL-12p70 for ratio comparison.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Fraction of screened patients enrolled, fraction of patients with complete sample collection, and fraction of patients with complete clinical data</measure>
    <time_frame>1-Year from Initial Enrollment</time_frame>
    <description>Estimate the feasibility of enrolling ARDS patient for a future larger trial designed to examine IL-10:IL-12p70 as a predictor of ARDS in pediatric patients. This study will generate pilot data regarding consent rate, estimates of data completion, and fraction of missing clinical data necessary for us to determine whether a future study involving the ratio of IL-10 to IL-12p70 can be used as a predictor of ARDS in this population.</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">0</enrollment>
  <condition>Acute Respiratory Failure</condition>
  <condition>Acute Respiratory Infection</condition>
  <condition>Acute Respiratory Distress Syndrome</condition>
  <arm_group>
    <arm_group_label>Respiratory Illness</arm_group_label>
    <description>Previously healthy patients admitted with acute respiratory illness who are then intubated requiring mechanical ventilator support. Endotracheally intubated patients of age 37 weeks gestation through 17 years with an acute respiratory illness in the absence of existing cardiopulmonary disease, tracheostomy, or immunocompromised condition. Tracheal aspirates (TA), bronchial fluid (nb-BALF), and blood are collected within 48-hours following endotracheal intubation. All three samples are collected again at two additional time points following intubation: between days 3-4 and between days 5-7, so long as the patient remains endotracheally intubated.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Will bank all remaining serum, tracheal secretion, and bronchial secretion de-identified for
      purposes of future unknown scientific studies designed at examining respiratory secretions in
      this defined pediatric population.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Previously healthy patients presenting to UNC with respiratory failure presumptively caused
        by a primary lung infection will be screened. Only those patients intubated within 48-hours
        of potential enrollment and between the ages of â‰¥37 weeks gestation and 17 years will be
        considered. For purposes of this study, acute respiratory illness is defined as having
        upper respiratory infection symptoms and/or lower respiratory tract infection. Patient
        should have fever (&gt;38 oC) OR leukocytosis / leukopenia (&gt;10,000 or &lt;2,000) AND any of the
        following: tachypnea, hypoxia (saturation &lt;97%), cough, congestion, rhinorrhea, abnormal
        lung exam findings, or infiltrate on chest x-ray.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Previously healthy

          -  Age 37 weeks gestation through 17 years

          -  Presumed respiratory infection

          -  Intubated &lt;48 hours

        Exclusion Criteria:

          -  Trauma, Drowning, Pancreatitis, or Sepsis not originating from a pulmonary infection.

          -  Pre-existing chronic disease including:

          -  congenital heart disease or acquired cardiomyopathy

          -  pulmonary hypertension

          -  restrictive lung disease

          -  cystic fibrosis

          -  asthma controlled with chronically inhaled steroids

          -  Tracheostomy

          -  Immunocompromised including chronic steroid use within last month

          -  Oncological condition except conditions in active remission not requiring maintenance
             chemotherapy.

          -  Intubated patient with an endotracheal tube &lt;3.5 mm

          -  Patients with persistent SpO2 &lt;90% despite adequate ventilator support, or patients
             deemed too unstable to undergo mini-BAL by the clinical care team
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Lercher, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of North Carolina Hospital at Chapel Hill</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Benny Joyner, MD, MPH</last_name>
    <role>Study Director</role>
    <affiliation>University of North Carolina, Chapel Hill</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Benny L Joyner, Jr., MD, MPH</last_name>
    <role>Study Chair</role>
    <affiliation>University of North Carolina, Chapel Hill</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of North Carolina Hospital at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 25, 2014</study_first_submitted>
  <study_first_submitted_qc>January 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2014</study_first_posted>
  <last_update_submitted>November 10, 2017</last_update_submitted>
  <last_update_submitted_qc>November 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Respiratory Secretions</keyword>
  <keyword>Tracheal Secretions</keyword>
  <keyword>Bronchial Secretions</keyword>
  <keyword>NonBronchoscopic BAL</keyword>
  <keyword>Interleukin 10</keyword>
  <keyword>Interleukin 12p70</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Respiratory Insufficiency</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

